Latest News

FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC
FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC

February 19th 2025

Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant advanced non–small cell lung cancer.

FDA Fast-Tracks IBI363 in Squamous NSCLC
FDA Fast-Tracks IBI363 in Squamous NSCLC

February 18th 2025

Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC

February 17th 2025

Wildfires’ Impact on Patients With Cancer: Lessons in Crisis Response
Wildfires’ Impact on Patients With Cancer: Lessons in Crisis Response

February 11th 2025

AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation
AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation

February 10th 2025

More News